West Virginia HB4721 amends Schedule I drugs to include crystalline polymorph psilocybin if approved by the FDA and DEA.

West Virginia HB4721 amends Schedule I drugs to include crystalline polymorph psilocybin, if approved by the United States Food and Drug Administration and the Drug Enforcement Administration. It allows for the lawful prescription, distribution, and marketing of this drug based on recommendations from the FDA and DEA. The bill maintains the classification of fentanyl and carfentanil as Schedule II substances.

West Virginia HB4721 amends Schedule I drugs to include crystalline polymorph psilocybin if approved by the FDA and DEA.

West Virginia HB4721 amends Schedule I drugs to include crystalline polymorph psilocybin, if approved by the United States Food and Drug Administration and the Drug Enforcement Administration. It allows for the lawful prescription, distribution, and marketing of this drug based on recommendations from the FDA and DEA. The bill maintains the classification of fentanyl and carfentanil as Schedule II substances.